scholarly journals No answer to the lack of specificity: mouse monoclonal antibody targeting the angiotensin II type 1 receptor AT1 fails to recognize its target

2018 ◽  
Vol 391 (8) ◽  
pp. 883-889 ◽  
Author(s):  
Marie-Lynda Bouressam ◽  
Isabelle Lartaud ◽  
François Dupuis ◽  
Sandra Lecat
2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Mingming Wei ◽  
Chengrui Zhao ◽  
Suli Zhang ◽  
Li Wang ◽  
Huirong Liu ◽  
...  

The current study was to prepare a mouse-derived antibody against the angiotensin II type 1 receptor (AT1-mAb) based on monoclonal antibody technology, to provide a foundation for research on AT1-AA-positive diseases. Balb/C mice were actively immunized with the second extracellular loop of the angiotensin II type 1 receptor (AT1R-ECII). Then, mouse spleen lymphocytes were fused with myeloma cells and monoclonal hybridomas that secreted AT1-mAb were generated and cultured, after which those in logarithmic-phase were injected into the abdominal cavity of mice to retrieve the ascites. Highly purified AT1-mAb was isolated from mouse ascites after injection with 1 × 107hybridomas. A greater amount of AT1-mAb was purified from mouse ascites compared to the cell supernatant of hybridomas. AT1-mAb purified from mouse ascites constricted the thoracic aorta of mice and increased the beat frequency of neonatal rat myocardial cells via the AT1R, identical to the effects of AT1-AA extracted from patients’ sera. Murine blood pressure increased after intravenous injection of AT1-mAb via the tail vein. High purity and good biological activity of AT1-mAb can be obtained from mouse ascites after intraperitoneal injection of monoclonal hybridomas that secrete AT1-mAb. These data provide a simple tool for studying AT1-AA-positive diseases.


1994 ◽  
Vol 141 (2) ◽  
pp. R5-R9 ◽  
Author(s):  
G. P. Vinson ◽  
M. M. Ho. ◽  
J.R. Puddefoot ◽  
R. Teja ◽  
S. Barker

ABSTRACT Little is known about the cellular localisation of the angiotensin II (AII) type 1 receptor (ATI) in the rat adrenal glomerulosa cell, but some studies have suggested that receptor internalisation and recycling may occur. Using a specific monoclonal antibody (6313/G2) to the first extracellular domain, we show here that most of the receptor is internalised in the unstimulated cell. When viable glomerulosa cells are incubated with 6313/G2, the receptor is transiently concentrated on the cell surface, and aldosterone output is stimulated. This stimulated output is enhanced by neither threshold nor maximal stimulatory concentrations of All amide, although the antibody does not inhibit All binding to the receptor. Conversely, the stimulatory actions of the antibody and those of ACTH are additive. The data suggest that recycling to the plasma membrane is constitutive, or regulated by unknown factors. Retention of the ATI receptor in the membrane is alone enough to allow sufficient G protein interaction to generate maximal stimulatory events.


2008 ◽  
Vol 197 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Fang Xiao ◽  
John R Puddefoot ◽  
Stewart Barker ◽  
Gavin P Vinson

The extracellular N-terminus of G-protein-coupled receptors may be involved in signalling events. We examined this in the angiotensin II type 1 receptor (AT1-R) using monoclonal antibody 6313/G2, raised against a conserved sequence in the N-terminal domain, and found it evokes inhibitory and stimulatory responses. In rat aortic smooth muscle cell (RASMC) primary cultures, 6313/G2 (2.5 μg/ml) inhibited both basal and angiotensin II (Ang II; 10−7 mol/l)-stimulated [H3]thymidine incorporation. Exposure to 6313/G2 gave sustained increases in phosphorylated protein kinase Cα (PKCα) but gave a decrease in phosphorylated p44/42 extracellular signal-regulated kinases (ERK1/2) sustained from 10 min to 48 h compared with untreated control RASMC. In contrast, Ang II had no effect on PKCα, and, though it is acutely stimulatory (up to 5 min), it had no sustained effect on ERK1/2 either. Using Fura-2 and microfluorimetry, 6313/G2 added alone induced a transient increase in intracellular calcium ([Ca2+]i), with a characteristic response curve different from that of Ang II itself. The antibody was without effect on an Ang II-stimulated activator protein-1 reporter system, though it reduced unstimulated reporter activity. Such discriminatory effects on intracellular signalling suggest that the AT1-R N-terminus itself might be a target for therapeutic intervention in chronic vascular disease.


1988 ◽  
Vol 178 (1) ◽  
pp. 333-336 ◽  
Author(s):  
Sydney Welt ◽  
Beatrice W.T. Yin ◽  
Koichi Furukawa ◽  
Karl-Anders Karlsson ◽  
Lloyd J. Old ◽  
...  

2009 ◽  
Vol 384 (3) ◽  
pp. 329-333 ◽  
Author(s):  
Seiji Kawa ◽  
Hirohisa Matsushita ◽  
Hirokazu Ohbayashi ◽  
Kentaro Semba ◽  
Tadashi Yamamoto

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e85002 ◽  
Author(s):  
Pan-Pan Hao ◽  
Yan-Ping Liu ◽  
Chang-Ya Yang ◽  
Ting Liang ◽  
Chao Zhang ◽  
...  

2020 ◽  
Author(s):  
Tomohiro Kotaki ◽  
Atsushi Yamanaka ◽  
Eiji Konishi ◽  
Masanori Kameoka

AbstractAnalysis of the neutralizing epitope of dengue virus (DENV) is important for the development of an effective dengue vaccine. A potent neutralizing mouse monoclonal antibody named 7F4 was previously reported and, here, we further analyze the detailed epitope of this antibody. 7F4 recognized a novel conformational epitope close to the N-67 glycan on the E protein. This antibody was specific to the DENV that lacks N-67 glycan, including the Mochizuki strain. Interestingly, the Mochizuki strain acquired N-67 glycan by 7F4 selective pressure. DENVs might have evolved to escape from this antibody considering that most of currently circulating DENVs possess N-67 glycan. However, this suggests that 7F4 epitope might be useless as a vaccine target. Nevertheless, this study demonstrated the existence of epitopes competing for 7F4 epitope, which are involved in neutralization. This study describes the importance of antibodies recognizing epitopes near the N-67 glycan for future dengue vaccine development.


Sign in / Sign up

Export Citation Format

Share Document